l-Glutamine and the Dawn of Combination Therapy for Sickle Cell Disease

In 2017, the U.S. Food and Drug Administration approved l-glutamine (USAN, glutamine) for the prevention of acute vaso-occlusive pain events in persons with sickle cell disease who are older than 5 years of age — only the first drug to be approved for this indication in the 20 years since the…

https://ift.tt/2uS8WNk